PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-yearInvivyd’s target of near-term profitability (1H 2025) was not met but remains ...

Leadership and talent actions -- Lisa Wolf confirmed as CFO; key hires from Statera joined for regulatory, clinical, and ...

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the ...

Vonaprument selected by EMA for the exclusive Product Development Coordinator (PDC) pilot launched in July 2025 to help Priority Medicine (PRIME) designation holders efficiently navigate regulatory ...

Pakistan is preparing to approach the United Nations Security Council (UNSC) to seek the designation of the Balochistan ...

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 ...

GAAP EPS loss of $0.41 in Q2 2025 beat analyst expectations for a larger loss of $0.48 per share. R&D expenses (GAAP) rose 19% to $23.4 million in Q2 2025 compared to Q2 2024, primarily due to higher ...

Larimar Therapeutics ( (LRMR) ) has issued an announcement. On August 14, 2025, Larimar Therapeutics reported its second quarter 2025 financial results, highlighting significant progress in its ...

Strengthened Balance Sheet With $65.1 Million Public Offering: In July 2025, Larimar announced a public offering of common stock with net proceeds of $65.1 million supported by existing and new ...

With a market cap of $3.1 billion, Scholar Rock Holding Corporation appears fairly valued for now. Click here to read an ...

Explore Inovio Pharmaceuticals' Q2 2025 earnings call highlights, including progress on INO-3107, regulatory milestones, financial updates, and ...